Arcus Biosciences Q4 net loss $67M; ARC-7 domvanalimab combo doubles PFS to 12 months

Arcus Biosciences, Inc.

2022-FY EPS reported -$3.71 revenue$112,000,000

Q4 2022 net loss $67M vs net income $280M in Q4 2021; full-year net loss $267M vs net income $53M.
Revenue $34M in Q4 2022, down from $355M in Q4 2021; cash $1.1B, sufficient into 2026.
ARC-7 interim data: domvanalimab+zimberelimab mPFS 12.0 months vs 5.4 months for zimberelimab alone.
Four ongoing registrational Phase 3 studies for domvanalimab; updated ARC-7 data expected at ASCO June 2023.
AB521 (HIF-2a inhibitor) Phase 1/1b enrolling 50mg cohort; initial data expected late 2023 or early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Arcus Biosciences, Inc. reported financial results for the three months and full year ended December 31, 2022.

Period: the three months and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 28, 2023, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months and full year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-005084

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.